Defective Uptake and Utilization of Long Chain Fatty Acids in Muscle and Adipose Tissues of CD36 Knockout Mice*
By C. Coburn, F. Knapp, M. Febbraio, A. Beets, R. Silverstein, N. Abumrad. Journal of Biological Chemistry, 2000
718 citations recorded by the source corpus.
The transmembrane protein CD36 has been identified in isolated cell studies as a putative transporter of long chain fatty acids. In humans, an association between CD36 deficiency and defective myocardial uptake of the fatty acid analog 15-(p-iodophenyl)-3-(R,S)-methyl pentadecanoic acid (BMIPP) has been reported. To determine whether this association represents a causal link and to assess the physiological role of CD36, we compared tissue uptake and metabolism of two iodinated fatty acid analogs BMIPP and 15-(p-iodophenyl) pentadecanoic acid (IPPA) in CD36 null and wild type mice. We also investigated the uptake and lipid incorporation of palmitate by adipocytes isolated from both groups. Compared with wild type, uptake of BMIPP and IPPA was reduced in heart (50–80%), skeletal muscle (40–75%), and adipose tissues (60–70%) of null mice. The reduction was associated with a 50–68% decrease in label incorporation into triglycerides and in 2–3-fold accumulation of label in diglycerides. Identical results were obtained from studies of [3H]palmitate uptake in isolated adipocytes. The block in diglyceride to triglyceride conversion could not be explained by changes in specific activities of the key enzymes long chain acyl-CoA synthetase and diacylglycerol acyltransferase, which were similar in tissues from wild type and null mice. It is concluded that CD36 facilitates a large fraction of fatty acid uptake by heart, skeletal muscle, and adipose tissues and that CD36 deficiency in humans is the cause of the reported defect in myocardial BMIPP uptake. In CD36-expressing tissues, uptake regulates fatty acid esterification at the level of diacylglycerol acyltransferase by determining fatty acyl-CoA supply. The membrane transport step may represent an important control site for fatty acid metabolism in vivo.
Subfields: Epidemiology, Molecular Biology, Physiology
View Paper: https://www.semanticscholar.org/paper/49ef54489dbf13e8ee83f0a9fe824f6270de37b9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Molecular Biology
In Physiology
Citations in the corpus
- Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research (2006, background): “CD36 null mouse exhibits elevated circulating LCFA and TG levels and hepatic IR due to impaired fatty acid storage; affected mice develop steatosis and fail to suppress hepatic gluconeogenesis (Coburn et al. 2000; Goudriaan et al. 2003).”
- Triglyceride metabolism in the liver (2017, neutral): “Whereas CD36 liver-specific deletion in mice leads to reduced hepatic lipid contents and decreased FA uptake in the setting of high fat feeding, suggesting the direct contribution of CD36 to hepatic FA metabolism under these conditions (279), whole body knockout of CD36 in mice significantly impairs”
- The role of FoxO in the regulation of metabolism (2008, background): “CD36 is a plasma membrane fatty acid translocase that facilitates fatty acid uptake into skeletal muscle (Coburn et al., 2000; Hajri and Abumrad, 2002; Hajri et al., 2002).”
- CD36, a Scavenger Receptor Involved in Immunity, Metabolism, Angiogenesis, and Behavior (2009, background): “Cd36-null mice show abnormal plasma lipid and lipoprotein prof iles and resting hypoglycemia (69), attributable in part to a marked impairment of fatty acid utilization in cardiac and striated muscle and of fatty acid uptake by adipose tissues (62).”